Low BUB1 expression is an adverse prognostic marker in gastric adenocarcinoma

Oncotarget
David StahlInes Gütgemann

Abstract

Gastric adenocarcinomas are associated with a poor prognosis due to the fact that the tumor has often metastasized by the time of diagnosis and prognostic markers are urgently needed to tailor treatment. We examined the expression of the mitotic spindle checkpoint protein BUB1 (budding uninhibited by benzimidazoles 1) and Ki-67 protein expression by immunohistochemistry in 218 patients with primary gastric adenocarcinomas. Tumors with low frequency of BUB1 expression were associated with larger tumor size (pT) (p < 0.001), higher incidence of lymph node metastases (pN) (p = 0.027), distant metastases (pM) (p = 0.006) and higher UICC stage (p < 0.001). Furthermore, BUB1 expression was inversely correlated with residual tumor stage (p = 0.038). Abundant BUB1 protein expression correlated with frequent Ki-67 protein expression (p < 0.001) and low BUB1 expression was associated with shorter survival (p < 0.001). Univariate and multivariate analyses confirmed BUB1 to be an independent prognostic marker in gastric cancer (p = 0.021).

References

Aug 1, 1997·American Journal of Clinical Oncology·D PectasidesA Athanassiou
Jun 19, 2001·Oncology Reports·H ShigeishiW Yasui
Oct 20, 2001·Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology·H ShigeishiW Yasui
Oct 17, 2007·The Journal of Cell Biology·Karthik JeganathanJan M van Deursen
May 6, 2008·The Breast : Official Journal of the European Society of Mastology·R Stuart-HarrisP Pharoah
Aug 10, 2010·Digestive Diseases and Sciences·Constantinos GiaginisStamatios Theocharis
Aug 27, 2010·Clinical Otolaryngology : Official Journal of ENT-UK ; Official Journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery·V PaleriR G Wight
Jun 8, 2011·The Journal of Cell Biology·Robin M RickeJan M van Deursen
Mar 10, 2012·Journal of Gastroenterology·Eiji OkiYoshihiko Maehara
Nov 15, 2012·Annals of Surgical Oncology·Manali I PatelGeorge A Poultsides
Nov 24, 2012·Current Biology : CB·Pablo Lara-GonzalezStephen S Taylor
Apr 23, 2014·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Yining ZhangMingjun Sun
Sep 16, 2014·International Journal of Cancer. Journal International Du Cancer·Jacques FerlayFreddie Bray
Oct 25, 2014·Neuroendocrinology·Marie-Louise F van VelthuysenCatharina M Korse
Dec 9, 2014·Cell Cycle·J Bargiela-IparraguirreI Sánchez-Pérez
Jul 8, 2015·Journal of Cell Science·Mathijs VleugelGeert J P L Kops
Jul 21, 2015·Nature Medicine·Andrew J GentlesAsh A Alizadeh
Aug 5, 2015·Human Pathology·Manuel H SchäferInes Gütgemann
Aug 28, 2015·Lancet·Abhik MukherjeeIan O Ellis
Nov 23, 2015·Molecular Cell·Carmen Dominguez-BrauerTak W Mak
Dec 29, 2015·Journal of Surgical Oncology·Christine BögerChristoph Röcken
Nov 27, 2016·Journal of Experimental & Clinical Cancer Research : CR·Wang LiuXiongwen Zhang

❮ Previous
Next ❯

Citations

Jul 8, 2018·International Journal of Cancer. Journal International Du Cancer·Giorgia SimonettiGiovanni Martinelli
Feb 6, 2020·Experimental and Therapeutic Medicine·Luyao WangJia Liu
Nov 3, 2020·Frontiers in Molecular Biosciences·Xiaowei ChenXiaobing Shen
Mar 7, 2021·Journal of Personalized Medicine·Noshad PeyravianEhsan Nazemalhosseini Mojarad

❮ Previous
Next ❯

Methods Mentioned

BETA
transgenic
biopsies

Software Mentioned

Tissue studio
SPSS

Related Concepts

Related Feeds

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.